

## Products under development

Active substance	Dosage form	Strength	Dossier Availability	Indication
Agomelatine	Film-coated tablets	25 mg	Q1 2017	Depression
Benfotiamine	Film-coated tablets	50 mg, 300 mg	Q2 2017	Vitamin B <sub>1</sub> Deficiency
Buprenorphine + Naloxone	Sublingual tablets	2 mg+0.5 mg, 4 mg+1 mg, 8 mg+2 mg	Q4 2016	Opioid Use Disorder
Esketamine	Solution for injection	5 mg/ml (5 ml), 25 mg/ml (2 ml, 5 ml, 10 ml, 50 ml)	Q2 2017	Severe Pain, Narcotic
Eslicarbazepine	Tablets	200 mg, 400 mg, 600 mg, 800 mg	Q1 2017	Epilepsy
Fesoterodine	Prolonged-release tablets	4 mg, 8 mg	Q2 2018	Overactive Bladder
Hydromorphone	Solution for injection	2 mg/ml, 10 mg/ml, 20 mg/ml, 50 mg/ml (1 ml), 10 mg/ml (10 ml)	Q2 2017	Severe Pain
Ketamine	Solution for injection	10 mg/ml (5 ml, 20 ml), 50 mg/ml (2 ml, 5 ml, 10 ml)	Q2 2017	Severe Pain, Narcotic
Levomethadone	Tablets	2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg	Q2 2017	Opioid Use Disorder
Metamizole	Solution for injection	500 mg/ml (2 ml, 5 ml)	Q4 2016	Mild to Moderate Pain
Methadone	Tablets	5 mg, 10 mg, 20 mg, 40 mg, 60 mg	Q2 2017	Opioid Use Disorder
Metoclopramide	Tablets	10 mg	Q4 2016	Nausea, Emesis
Prasugrel	Film-coated tablets	5 mg, 10 mg	Q2 2017	Antithrombotic
Vitamin B <sub>1</sub> /B <sub>2</sub> /B <sub>3</sub> /B <sub>5</sub> /B <sub>6</sub> (Multivit-B® forte plus)	Solution for injection	5 mg+2.5 mg+10 mg+22 mg+2.85 mg/ml (10 ml)	Q4 2016	B Vitamin Deficiency
Tizanidine	Tablets	2 mg, 4 mg, 6 mg	Q4 2017	Muscle Spasms

Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement.  
 Products protected by patents will not be supplied in countries where the respective patents are valid.